# Shares of Pfizer Inc. (PFE) have underperformed the broader market over the past year.

*biotech · news · 2026-04-28 · Barchart*

## Key points

- Pfizer is targeting $600 million in manufacturing cost savings for 2025.
- The Pfizer/Valneva Lyme vaccine showed 73%-75% efficacy but missed its primary endpoint.
- Analyst consensus on Pfizer stock has become slightly more bullish over the past two months.
- Pfizer’s GLP-1 obesity drug PF-3944 is a key post-2028 growth bet.

**Companies:** Pfizer Inc.
**Countries:** United States

[Read the full story on Barchart](https://www.barchart.com/story/news/1561694/are-wall-street-analysts-bullish-on-pfizer-stock)

---

Canonical: https://newsio.io/n/d37d2c57-2694-44c3-a737-3af3ca2d2769/shares-of-pfizer-inc-pfe-have-underperformed-the-broader-market-over-the-past-ye
Summarized by Newsio from Barchart. https://newsio.io/how-it-works